Semax vs N-Acetyl Semax: Stability, Potency & Research Protocol Differences

Research comparison of standard Semax vs N-Acetyl Semax Amidate (NASSA) — acetylation and amidation modifications for improved stability and potency, dose equivalence, nasal spray reconstitution, and which form is appropriate for which research goal.

TL;DR

• Standard Semax (ACTH 4-7 Pro8 Gly9 Pro10): effective intranasal BDNF/NGF-modulating peptide; 500-1000mcg research dose
• N-Acetyl Semax Amidate (NASSA): N-terminus acetylated + C-terminus amidated → ~3-7x more potent, more stable
• NASSA typical dose: 50-300mcg intranasally (much lower than standard Semax)
• Both use identical intranasal delivery; NASSA preferred for cost-efficiency at higher experience level

Disclaimer: For educational and research purposes only — not medical advice.

Semax is a synthetic heptapeptide derived from the ACTH 4-10 fragment, developed at the Institute of Molecular Genetics in Russia and approved there for treating stroke recovery and cognitive impairment. It has gained significant interest in Western nootropic research for its BDNF-modulating, neuroprotective, and cognitive-enhancing properties. The modified variant, N-Acetyl Semax Amidate (NASSA), represents a next-generation form with improved pharmacokinetics that has largely supplanted standard Semax among experienced researchers.

Standard Semax: The Foundation

Structure: Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 with modifications at positions 8, 9, 10)

Mechanisms:

• Increases BDNF (brain-derived neurotrophic factor) in the hippocampus and frontal cortex
• Modulates ACTH receptor pathways (attention, arousal)
• Reduces dopamine metabolism (prolongs dopaminergic signaling)
• Anti-inflammatory in the CNS (reduces microglial activation)
• Neuroprotective against hypoxia and stroke damage

Administration: Intranasal (nasal spray or dropper solution) — bypasses the BBB via olfactory epithelium

Standard research doses: 500-1000mcg (0.5-1mg) per dose, 1-2x daily

Half-life: Standard Semax has a relatively short effective half-life in nasal secretions due to peptidase degradation — limiting exposure duration

N-Acetyl Semax Amidate (NASSA): Enhanced Form

Modifications:

1. N-Acetylation: An acetyl group added to the N-terminus blocks aminopeptidase enzymes that would otherwise cleave the peptide from that end
2. C-Amidation: The C-terminus carboxyl (-COOH) is converted to an amide (-CONH2), protecting against carboxypeptidase degradation and altering receptor binding dynamics

Pharmacological consequences:

• Resistance to enzymatic degradation in nasal mucus → longer effective exposure in olfactory epithelium
• Increased receptor binding affinity (amidation commonly improves potency)
• More consistent absorption through nasal mucosa
• Estimated 3-7x higher potency compared to unmodified Semax

Research dose range: 50-300mcg per dose — dramatically lower than standard Semax reflecting the potency advantage

Head-to-Head Comparison

Reconstitution for Intranasal Use

Both forms are used identically via intranasal administration:

Nasal spray reconstitution:

• Semax: 10mg vial + 10mL distilled or preserved water → 1mg/mL solution

• 1000mcg dose = 1 mL (fill nasal spray bottle with ~0.5mL per nostril)

• NASSA: 10mg vial + 10mL water → 1mg/mL solution

• 100mcg dose = 0.1mL (10 doses per mL); typically 5-10 drops per nostril (using 1 drop per ~10mcg with standard dropper)

Storage: Reconstituted intranasal solutions refrigerate at 4°C; use within 3-4 weeks. Lyophilized vials store at -20°C indefinitely.

Nasal spray bottle: Commercially available nasal spray pump bottles (10-30mL) calibrated at 0.1mL/spray work well for consistent dosing.

Which Form to Start With?

Start with standard Semax if:

• First time researching Semax peptides (learn effects at lower potency)
• Budget-conscious (lower cost per mg, though higher dose required)
• Comparing to published research (most clinical studies used standard Semax)

Progress to NASSA if:

• Standard Semax effects are well-established
• Seeking more potent effects at lower doses
• Cost-efficiency matters (lower per-dose volume, less waste)
• Interested in maximum neuroprotective potential

Frequently Asked Questions

Q: Can NASSA cause overstimulation at typical doses? A: At recommended starting doses (50-100mcg), NASSA is generally well-tolerated. Some researchers report mild anxiety, restlessness, or irritability — similar to standard Semax but at much lower doses. Starting at 50mcg and titrating up over weeks is the conservative approach. Reducing dose or frequency typically resolves these effects.

Q: Is NASSA available commercially as a nasal spray? A: NASSA is available as a lyophilized powder from research peptide suppliers. Some nootropics vendors sell pre-mixed nasal spray solutions. For research purposes, reconstituting from powder provides better dose control and freshness assurance.

Use the Dosage Calculator → /calculators/dosage

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions